The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia

The goal of this clinical trial is to learn about in health conditions. The main questions it aims to answer are:

* The pathological significance of GPER in uterine artery dilation in preeclampsia * The Mechanism of GPER Hippo Pathway Regulating CBS/H2S in Human Uterine Artery Smooth Muscle Cells (hUASMC) This project intends to use GPER interfering RNA, YAP1 interfering RNA, in vivo perfusion experiments of human uterine artery tissue, and single cell patch clamp technology to study hypotheses under physiological/pathological pregnancy conditions at the tissue, cellular, and molecular levels, revealing a novel signal transduction pathway of estrogen stimulating vasodilation, providing new ideas for studying the mechanism of uterine artery blood flow regulation. This research result will provide new targets for intervention and treatment of diseases such as fetal intrauterine growth retardation and preeclampsia.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Preeclampsia Female Urogenital Diseases and Pregnancy Complications Hypertension, Pregnancy-Induced Pre-Eclampsia Pregnancy Complications Urogenital Diseases

Age range

Up to 40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Shandong First Medical University &Shandong Provincial Qianfoshan Hospital

Jinan, Please Select, 250000, China

About this study

Measure the content of H2S in uterine arterial smooth muscle and circulation of normal pregnancy and PE pregnant women, and analyze the relationship between the content of H2S in uterine arterial smooth muscle and circulation of PE pregnant women and PE.
Knock down the GPER and overexpression of GPER in HTR-8 cells, and detect the expression of GPER, CBS, and Hippo pathway related proteins using Western blot and qRT-PCR to verify the efficiency of knockdown and overexpression. Use different concentrations of H2S donor (GYY4137) to interfere with HTR-8 cells after treatment, and use RT-PCR and Western blot to detect the mRNA and protein expression of downstream molecules YAP and TAZ in Hippo pathway in cells, respectively.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Full term pregnancy with clinical diagnosis of preeclampsia and normal pregnancy pregnant woman
Pregnant women undergoing lower segment cesarean section for delivery

Exclusion criteria

Combined with chronic hypertension, kidney disease, intrahepatic cholestasis, etc Other basic diseases;
Multiple pregnancy
Pregnant women undergoing vaginal delivery
Normal pregnant women who are<37 weeks or>40 weeks pregnant

Treatment and study plan

H2S content

Other

H2S content

Primary outcomes

H2S content in uterine arterial smooth muscle circulation

Time frame: 8:00 am

H2S content in circulation

Sponsors and collaborators

Lead sponsor

Hao Feng

Other

Registry information

Official study title

The Role and Mechanism of GPER Hippo Pathway in Regulating Uterine Arterial Smooth Muscle CBS/H2S in the Pathogenesis of Preeclampsia

Important dates

Study start: 2024
Primary completion: 2029
Study completion: 2029
First posted: Jan 16, 2024
Registry last updated: Apr 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation